Drug makers including BioNTech and Moderna are scrambling to test their COVID-19 vaccines against the new fast-spreading variant of the virus that is raging in Britain, the latest challenge in the breakneck race to curb the pandemic.
For more coronavirus news, visit our dedicated page.
Ugur Sahin, chief executive of Germany’s BioNTech, which with partner Pfizer took less than a year to get a vaccine approved, said on Tuesday he needs another two weeks to know if his shot can stop the mutant variant of the virus.
For all the latest headlines follow our Google News channel online or via the app
Moderna expects immunity from its vaccine to protect against the variant and is performing more tests in coming weeks to confirm, the company said in a statement to CNN. Moderna did not immediately respond to Reuters’ requests for comment.
The new coronavirus variant in Britain: Everything we know so far
The mutation known as the B.1.1.7 lineage may be up to 70 percent more infectious and more of a concern for children. It has sown chaos in Britain, prompting a wave of travel bans that are disrupting trade with Europe and threatening to further isolate the island country.
Sahin said there are nine mutations on the virus.
While he does not believe any are significant enough to skirt the protection afforded by BioNTech’s mRNA vaccine, which was approved by the European Union on Monday, he said another 14 days or so of study and data collection are needed before offering a definitive answer.
“Scientifically it is highly likely that the immune response by this vaccine can also deal with this virus variant,” he said on a call with reporters.
“The vaccine contains more than 1,270 amino acids, and only 9 of them are changed (in the mutant virus). That means that 99 percent of the protein is still the same.”
Germany’s CureVac said it does not expect the variant to affect the efficacy of its experimental shot, which is based on the same messenger RNA (mRNA) technology used by Pfizer-BioNTech.
It started late stage clinical trials on its vaccine candidate last week and is constantly reviewing variants, which the company said are common as viruses spread.
Even though there are multiple mutations, BioNTech’s Sahin said, most of the sites on the virus that are recognized by the body’s T-cell response are unchanged, and multiple antibody binding sites are also conserved.
In the event that the variant presents vaccine developers with an unexpected challenge, an advantage of mRNA is that scientists can quickly re-engineer genetic material in the shot to match that of the mutated protein, whereas modifying traditional vaccines would require extra steps.
“In principle, the beauty of the mRNA technology is we can directly start to engineer a vaccine which completely mimics this new mutation,” Sahin said.
“We could be able to provide a new vaccine technically within six weeks. Of course, this is not only a technical question. We have to deal with how regulators... would see that.”
Britain’s chief scientific adviser Patrick Vallance said on Saturday vaccines appeared to be adequate in generating an immune response to the variant of the coronavirus.
The World Health Organization (WHO) said on Tuesday it will convene a meeting of members to discuss strategies to counter the mutation.
Coronavirus: Sweden stands by COVID-19 strategy despite tighter measuresSweden is continuing to pursue the same strategy against the COVID-19 pandemic, despite a recent slew of stricter measures, Prime Minister Stefan ... Coronavirus
BioNTech-Pfizer to supply 12.5 mln doses of coronavirus vaccine to EU by year-endBioNTech and US drugmaker Pfizer will supply 12.5 million doses of their COVID-19 vaccine to the European Union by the end of the year, the German ... Coronavirus
WHO calls meet on new coronavirus strain, European head urges more preventive stepsThe World Health Organization (WHO) will convene a meeting of members to discuss strategies to counter a new, more infectious coronavirus strain that ... Coronavirus
Germany extends ban on UK, S. Africa arrivals until Jan 6 over new coronavirus strainGermany on Tuesday extended a ban on arrivals from Britain, Northern Ireland and South Africa until January 6 after a new more infectious coronavirus ... Coronavirus
Coronavirus: BioNTech says mutation-beating vaccine can be ready in six weeksThe co-founder of BioNTech said Tuesday it was “highly likely” that its vaccine against the coronavirus works against the mutated strain detected in ... Coronavirus
Coronavirus: France expects national COVID-19 vaccine approval by December 26French Health Minister Olivier Veran said on Tuesday that the French medical regulatory body was expected to give approval to COVID-19 vaccines by ... Coronavirus